Biotech


  • money
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Will the first approved psychedelic become a blockbuster?

    Compass and Usona are vying for an FDA first, but pricing, payer coverage and patient access could determine the commercial winner.

    By Meagan Parrish • Nov. 20, 2026
  • Illustration of cancer cells with textured surfaces against a dark blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Erasca data add to pressure facing Revolution’s breakthrough cancer drug

    Rasonque is already off to one of the best oncology launches in history. But certain limitations leave an opportunity that companies like Erasca — which is nearing the start of a Phase 3 trial — may be able to exploit. 

    By • Nov. 20, 2026
  • Explore the Trendline➔
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip
    Trendline

    Emerging biotech

    New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

    By BioPharma Dive staff
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Celldex drug stumbles in eczema; Epigenetic editing startup cuts staff

    Wall Street analysts rushed to Celldex’s defense following the setback. Elsewhere, Isomorphic Labs cut a cancer-focused deal with Merck and Teva’s research chief accepted a new job.

    By • Nov. 20, 2026
  • A double exposure photo illustration of a glass flask and a scientist holding a tube in a laboratory, with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    This week in charts

    This week in charts: Biotech investors’ China bets are already paying off

    This year, companies built around medicines from China have sped toward acquisitions or IPOs. Meanwhile, Summit is no longer the Wall Street darling it was in 2024. 

    By • Nov. 20, 2026
  • A person looks through a pipette while working at a laboratory bench.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    China could ‘corner’ biopharma sector with new plan, US panel warns

    A commission called on U.S. lawmakers to act quickly to prevent an “overdependence” on China that could leave American patients “vulnerable to supply chain weaponization.”

    By • Nov. 19, 2026
  • A photo of the exterior of Regeneron.
    Image attribution tooltip
    Permission granted by Regeneron
    Image attribution tooltip

    With FDA nod, Regeneron brings an RNAi drug to autoimmune disease

    The product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx. 

    By • Nov. 19, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

    The FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.

    By BioPharma Dive staff • Nov. 18, 2026
  • An illustration of a pill over an abstract background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    AI drugmaker Isomorphic restocks with $5B fundraise

    Even as the larger AI industry faces turmoil, investors have given Isomorphic the two largest cash infusions in the biotech sector this year.

    By Kristin Jensen • Nov. 17, 2026
  • A picture of the team at Marrow Therapeutics.
    Image attribution tooltip
    Permission granted by Marissa Fiorucci
    Image attribution tooltip
    Startup launches

    Marrow sets out to challenge genetic medicines for severe blood diseases

    Armed with $173 million in venture funding, the startup is developing what it’s positioning as a more accessible alternative to gene therapy and gene editing treatments for sickle cell and beta thalassemia.

    By • Nov. 17, 2026
  • Scientists reviewing datat on a computer
    Image attribution tooltip
    Kobus Louw via Getty Images
    Image attribution tooltip
    Sponsored by SAS

    Your AI pilots aren’t stalling because of the AI – they’re stalling because of your environment

    As clinical AI adoption accelerates, trust, traceability and readiness matter more than ever.

    By Kayt Leonard, Global Director, SAS • Nov. 16, 2026
  • A group of investors at Sofinnova Partners.
    Image attribution tooltip
    Permission granted by Sofinnova Partners
    Image attribution tooltip
    Emerging biotech

    One of Europe’s leading VCs banks a €725M ‘crossover’ fund

    Sofinnova Partners, which has backed the likes of successful drugmakers such as Abivax, Argenx and Verona Pharma, will use the cash to support a new group of later-stage biotechs.

    By • Nov. 16, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Novo submits sickle cell drug; Flagship, Gates Foundation deepen ties

    Novo views the medicine, acquired in a billion-dollar deal, as a future blockbuster. Meanwhile, a pair of startups forged an RNA editing pact and Astellas lined up two new trials in pancreatic cancer.

    By BioPharma Dive staff • Nov. 13, 2026
  • A double exposure photo illustration of a glass flask and a scientist holding a tube in a laboratory, with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    This week in charts

    This week in charts: Brain drugs are back on venture capitalists’ minds

    Five neurology-focused startups have together raised around $450 million in the last few weeks. Elsewhere, investors had a muted response to the latest cell therapy research.

    By • Nov. 13, 2026
  • Nasdaq signage at Broadway and West 44th Street in New York City's Times Square.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Windward prices $175M IPO to advance China-licensed lung drugs

    The Swiss biotech, which pocketed another $50 million through a concurrent private share sale to Sanofi, is developing a potential competitor to the blockbuster asthma treatment Tezspire.

    By • Nov. 12, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning

    The deal gives AstraZeneca a simpler way to make conjugate vaccines. Elsewhere, a psychedelic depression drug was submitted to the FDA and an autoimmune disease-focused biotech’s shares collapsed.

    By BioPharma Dive staff • Nov. 11, 2026
  • An illustration of beta amyloid plaques and tau in the brain
    Image attribution tooltip
    National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
    Image attribution tooltip
    Brain drug revival

    London biotech Oyster harvests $60M for tau-targeting brain drugs

    Oyster says a tweak it's made to traditional protein degrading technology can help break down tau, which has long been a focus of Alzheimer’s drug research.

    By • Nov. 10, 2026
  • A horizontal photo depicting the top of the U.S. Capitol set against a blue sky.
    Image attribution tooltip
    Tom Brenner/Getty Images via Getty Images
    Image attribution tooltip
    China competition

    BIO unveils plan for US to remain biotech’s ‘global leader’

    A seven-part proposal from the prominent lobbyist lays out a series of initiatives to accelerate drug development in the U.S. and counter China’s fast rise.

    By • Nov. 10, 2026
  • A 3D illustration of a human liver.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Vir hepatitis D drug succeeds in first pivotal study

    A program that’s survived Vir’s pivot away from infectious disease research hit all of its study objectives and appeared more potent than a rival drug also in late-stage development.

    By • Nov. 9, 2026
  • Vivek Ramaswamy embraces a woman onstage at an Ohio Republican election-night event in Columbus, Ohio.
    Image attribution tooltip
    Jon Cherry via Getty Images
    Image attribution tooltip
    Trump administration

    Ramaswamy’s biotech baggage haunted his political run

    A pivotal Alzheimer’s trial tied to Vivek Ramaswamy’s political rise is a tale of failed endpoints.

    By Sy Mukherjee • Nov. 9, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down

    The deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier recently acquired failed a key trial and Ultragenyx announced staff cuts.

    By BioPharma Dive staff • Nov. 6, 2026
  • A double exposure photo illustration of a glass flask and a scientist holding a tube in a laboratory, with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    This week in charts

    This week in charts: 3 drug launches Wall Street is watching

    The latest installment in BioPharma Dive’s visualization-focused series features a look at investors’ response to a trio of medicines highlighted in quarterly earnings this week.

    By • Nov. 6, 2026
  • A photo of the packaging for the pancreatic cancer drug Rasonque
    Image attribution tooltip
    Retrieved from Revolution Medicines.
    Image attribution tooltip

    Revolution’s Rasonque off to best cancer drug launch ‘in history’

    Wall Street analysts are already resetting projections for Rasonque — but company executives cautioned that it’s too early to draw conclusions about the pancreatic cancer drug’s launch trajectory.

    By Kristin Jensen • Nov. 5, 2026
  • An illustration of a bispecific antibody (yellow and orange) binding to two different membrane proteins (purple and blue).
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    T-Therapeutics reloads with a $133M megaround for bispecifics

    The startup is built around technology it claims can help get after known, but undruggable cancer targets and design particularly selective autoimmune disease treatments.

    By • Nov. 5, 2026
  • Two scientists work in a laboratory at Alethio Therapeutics' headquarters.
    Image attribution tooltip
    Permission granted by Alethio Therapeutics
    Image attribution tooltip
    Startup launches

    Alethio raises $90M to target rare blood cancers

    The startup is working on a medicine one of its investors claimed could have a broader reach than other approved drugs for a group of conditions known as myeloproliferative neoplasms.

    By • Nov. 5, 2026
  • An image of people cheering and holding up American flags
    Image attribution tooltip
    Jim Vondruska / Stringer via Getty Images
    Image attribution tooltip
    Trump administration

    Biopharma likely to climb higher after ‘blue wave,’ analysts say

    Historical data suggests the sector outperforms after midterm elections. And Democrats, newly in control of Congress, have “bigger fish to fry” than drug pricing, analysts said.

    By • Nov. 4, 2026